A. Menarini
Pfizer

DAIICHI SANKYO EUROPE GMBH

Featured products of Daiichi Sankyo
edoxaban
Packing/Price
28's
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AF03 - edoxaban : Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.
edoxaban
Packing/Price
28's (P147.00/film-coated tab)
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AF03 - edoxaban : Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.
olmesartan medoxomil, amlodipine besylate
Packing/Price
28's (P1,749.30/pack)
MIMS Class
Angiotensin II Antagonists, Calcium Antagonists, Anti-Anginal Drugs
ATC Classification
C09DB02 - olmesartan medoxomil and amlodipine : Belongs to the class of angiotensin II receptor blockers (ARBs) and calcium channel blockers. Used in the treatment of cardiovascular disease.
olmesartan medoxomil, amlodipine besylate
Packing/Price
28's (P2,228.52/pack)
MIMS Class
Angiotensin II Antagonists, Calcium Antagonists, Anti-Anginal Drugs
ATC Classification
C09DB02 - olmesartan medoxomil and amlodipine : Belongs to the class of angiotensin II receptor blockers (ARBs) and calcium channel blockers. Used in the treatment of cardiovascular disease.
olmesartan medoxomil
Packing/Price
30's (P1,298.67/pack)
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil : Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
olmesartan medoxomil
Packing/Price
30's (P1,528.09/pack)
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil : Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
olmesartan medoxomil
Packing/Price
30's (P2,403.91/pack)
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil : Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
Distributed by A. Menarini
edoxaban
Packing/Price
28's
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AF03 - edoxaban : Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.
edoxaban
Packing/Price
28's (P147.00/film-coated tab)
MIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AF03 - edoxaban : Belongs to the class of direct factor Xa inhibitors. Used in the treatment of thrombosis.
Distributed by Pfizer
olmesartan medoxomil, amlodipine besylate
Packing/Price
28's (P1,749.30/pack)
MIMS Class
Angiotensin II Antagonists, Calcium Antagonists, Anti-Anginal Drugs
ATC Classification
C09DB02 - olmesartan medoxomil and amlodipine : Belongs to the class of angiotensin II receptor blockers (ARBs) and calcium channel blockers. Used in the treatment of cardiovascular disease.
olmesartan medoxomil, amlodipine besylate
Packing/Price
28's (P2,228.52/pack)
MIMS Class
Angiotensin II Antagonists, Calcium Antagonists, Anti-Anginal Drugs
ATC Classification
C09DB02 - olmesartan medoxomil and amlodipine : Belongs to the class of angiotensin II receptor blockers (ARBs) and calcium channel blockers. Used in the treatment of cardiovascular disease.
olmesartan medoxomil
Packing/Price
30's (P1,298.67/pack)
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil : Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
olmesartan medoxomil
Packing/Price
30's (P1,528.09/pack)
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil : Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.
olmesartan medoxomil
Packing/Price
30's (P2,403.91/pack)
MIMS Class
Angiotensin II Antagonists
ATC Classification
C09CA08 - olmesartan medoxomil : Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in